roniciclib + docetaxel

Roniciclib + docetaxel is an investigational combination therapy consisting of roniciclib, a potent oral pan-cyclin-dependent kinase (CDK) inhibitor, and docetaxel, a well-established taxane-class chemotherapeutic agent. Roniciclib inhibits multiple CDKs involved in cell cycle progression and transcriptional regulation, thereby inducing cell cycle arrest and apoptosis in cancer cells. Docetaxel stabilizes microtubules and prevents their depolymerization, leading to mitotic arrest and cell death. The combination has been studied for synergistic antitumor activity in advanced solid tumors such as non-small cell lung cancer (NSCLC), with the rationale that dual targeting of the cell cycle machinery may enhance efficacy over monotherapy[3][5][6].